OncLive TV

Ticiana A. Leal, MD, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer.

Manfred Welslau, MD, discusses​ the interim results of the REFLECT trial in diffuse large B-cell lymphoma.

Elaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.

Ann H. Partridge, MD, MPH, discusses the role of genomic testing in breast cancer.

Omid Hamid, MD, discusses the utility of tumor mutational burden as a biomarker for response to immunotherapy in patients with melanoma.

Patricia Pautier, MD, discusses the toxicity profile of doxorubicin with trabectedin in the phase 2 LMS-02 trial in patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Joshua K. Sabari, MD, discusses novel immunotherapy combinations that are under investigation in non–small cell lung cancer.

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Lori A. Leslie, MD, lymphoma attending, discusses frontline treatment options in follicular lymphoma.

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the role of extended adjuvant endocrine receptor–positive breast cancer.

Nabil F. Saba, MD, FACP, discusses ​scheduling challenges with cisplatin in head and neck cancer.

Steven Lee Chang, MD, discusses the impact of the coronavirus disease 2019 on the surgical management of patients with genitourinary cancers.

Lori A. Leslie, MD, discusses a phase 1b study with tazemetostat plus lenalidomide and rituximab in patients with follicular lymphoma.

Alan P. Z. Skarbnik, MD, discusses the watch-and-wait approach in patients with follicular lymphoma.

John M. Burke, MD, discusses the role of tazemetostat in EZH2-mutated follicular lymphoma.

Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.

Edward B. Garon, MD, discusses unique challenges of the coronavirus disease 2019 in lung cancer.

Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.

Edward Chu, MD, MMS, discusses the impact of the phase 3 MK-3475-177/KEYNOTE-177 trial in ​metastatic colorectal cancer.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​the utility of sacituzumab govitecan-hzi​y in metastatic triple-negative breast cancer.

John A. Abraham, MD, FACS, discusses future research efforts in tenosynovial giant cell tumor.

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.

Shambavi Richard, MD, discusses treatment according to transplant eligibility in multiple myeloma. 

Neeta Somaiah, MD, discusses ​remaining challenges in soft tissue sarcoma.

Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.

Kevin Harrington, BSc, MBBS, PhD, MRCP, FRCP, FRCR, discusses the randomized phase 3 KEYNOTE-048 trial in recurrent/metastatic head and neck squamous cell carcinoma.

Praful K. Ravi, MD, discusses the evolving treatment landscape of advanced bladder cancer.